Nasdaq

Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog

NEEDHAM, Mass., June 26, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) approved ...
FiercePharma

Mycapssa data pad case for Chiasma's oral alternative to acromegaly injections

It took four years for Chiasma to bring its acromegaly pill Mycapssa back from the dead, but in late June, the Needham, Massachusetts-based biopharma did just that, scoring a nod for what's now the ...
Nasdaq

Chiasma to Host an Expert Panel on Acromegaly and the MPOWERED® Phase 3 Trial Results

NEEDHAM, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize ...
Business Insider

Chiasma Presents New Positive Data for MYCAPSSA from Phase 3 Trial MPOWERED™ for the Maintenance Treatment of Acromegaly at ENDO 2021

--Data supports MYCAPSSA® as non-inferior to long-actinginjectable somatostatin receptor ligands (iSRLs)-- --Data demonstrated patients taking MYCAPSSA had significant improvement in acromegaly ...
FiercePharma

Chiasma posts data on benefits of oral acromegaly drug over long-acting injectable rivals

Chiasma has released phase 3 data supporting its belief that acromegaly patients will prefer to take its oral formulation over existing long-acting injectables. The oral formulation, Mycapssa, came to ...
Reuters

Chiasma Announces FDA Approval Of Mycapssa Capsules

* CHIASMA INC - PLANS TO SCALE-UP ITS CUSTOMER FACING TEAM IN SALES, PATIENT SERVICES & MARKET ACCESS TO ABOUT 45 EMPLOYEES * CHIASMA INC - 'PLANS TO PRICE MYCAPSSA COMPETITIVELY WITH FASTEST GROWING ...
The Business Journals

Needham's Chiasma to be acquired by U.K. biopharma in all-stock deal

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Chiasma launched its first commercial product last year ...
Reuters

Chiasma Enters Into Revenue Interest Financing Agreement For Up To $75 Mln With Healthcare Royalty Partners

* CHIASMA INC - UNDER TERMS OF AGREEMENT, CHIASMA WILL RECEIVE $25 MILLION FROM HCR ON APRIL 14 * CHIASMA INC - IS ENTITLED TO RECEIVE AN ADDITIONAL $25 MILLION UPON U.S. FDA APPROVAL OF MYCAPSSA * ...
Business Insider

Chiasma to Present New Data from Two Phase 3 Trials, CHIASMA OPTIMAL and MPOWERED™, at ENDO 2021

NEEDHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology ...
BioWorld

Amryt rocks the Chiasma, no clash over synergies in stock deal

As investors await an MAA submission to the EMA for U.S.-approved Mycapssa (octreotide) in acromegaly, Chiasma Inc. disclosed its plan to merge with Amryt plc in an all-stock deal, thereby gaining a ...
Business Wire

Chiasma Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Chiasma, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Chiasma, Inc. (NASDAQ: CHMA) to Amryt Pharma plc is fair to Chiasma shareholders.